We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+27.66%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$153M
AUM Growth
+$16.6M
Cap. Flow
-$12.7M
Cap. Flow %
-8.29%
Top 10 Hldgs %
60.22%
Holding
56
New
20
Increased
9
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
AMRI
Albany Molecular Research Inc
AMRI
+$6.17M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$3.47M
3
PFE icon
Pfizer
PFE
+$3.14M
4
BIS icon
ProShares UltraShort NASDAQ Biotechnology
BIS
+$2.09M
5
SNY icon
Sanofi
SNY
+$1.27M

Top Sells

Rank Stock Value
1
ANIP icon
ANI Pharmaceuticals
ANIP
+$9.34M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$8.69M
3
FRX
FOREST LABORATORIES INC
FRX
+$4.22M
4
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$4.11M
5
GSK icon
GSK
GSK
+$2.45M

Sector Composition

Rank Sector Weight
1 Miscellaneous 64.67%
2 Healthcare 35.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$827B
$18.7M 12.23%
100,000
+50,000
+100% +$9.18M
MDY icon
2
PUT
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$26.7B
$12.5M 8.2%
50,000
-20,000
-29% -$4.9M
TWM icon
3
CALL
ProShares UltraShort Russell2000
TWM
$43.9M
$11.5M 7.5%
12,500
+11,250
+900% +$10.7M
AMRI
4
DELISTED
Albany Molecular Research Inc
AMRI
$8.33M 5.45%
+448,200
New +$6.17M
AUXL
5
CALL
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$8.15M 5.33%
+300,000
New +$7.96M
WCG
6
PUT
DELISTED
Wellcare Health Plans, Inc.
WCG
$7.94M 5.19%
+125,000
New +$8.1M
BAX icon
7
CALL
Baxter International
BAX
$13.4B
$7.36M 4.81%
+184,100
New +$6.88M
TEVA icon
8
Teva Pharmaceuticals
TEVA
$43.8B
$6.87M 4.49%
130,000
+75,000
+136% +$3.47M
IWM icon
9
PUT
iShares Russell 2000 ETF
IWM
$81.9B
$5.82M 3.81%
50,000
– –
AUXL
10
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$4.88M 3.19%
179,481
-155,000
-46% -$4.11M
DGX icon
11
Quest Diagnostics
DGX
$27B
$4.47M 2.93%
77,208
– –
MRK icon
12
Merck
MRK
$369B
$4.37M 2.86%
80,696
– –
ANIP icon
13
ANI Pharmaceuticals
ANIP
$1.69B
$4.19M 2.74%
133,558
-351,852
-72% -$9.34M
TEVA icon
14
CALL
Teva Pharmaceuticals
TEVA
$43.8B
$3.96M 2.59%
75,000
-125,000
-63% -$5.78M
AZN icon
15
AstraZeneca
AZN
$255B
$3.71M 2.43%
57,239
-25,000
-30% -$1.61M
QLTI
16
DELISTED
QLT Inc
QLTI
$3.48M 2.28%
626,639
+100,000
+19% +$620K
HNT
17
CALL
DELISTED
HEALTH NET INC
HNT
$3.4M 2.22%
100,000
+50,000
+100% +$1.64M
HNT
18
DELISTED
HEALTH NET INC
HNT
$3.4M 2.22%
100,000
– –
PFE icon
19
Pfizer
PFE
$160B
$3.21M 2.1%
+105,400
New +$3.14M
SNY icon
20
Sanofi
SNY
$107B
$3.02M 1.97%
57,735
+25,000
+76% +$1.27M
BIS icon
21
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
$2.23M 1.46%
+3,125
New +$2.09M
VXX
22
CALL
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
$2.11M 1.38%
+3,125
New +$2.2M
AMRI
23
CALL
DELISTED
Albany Molecular Research Inc
AMRI
$1.86M 1.22%
+100,000
New +$1.38M
SUPN icon
24
CALL
Supernus Pharmaceuticals
SUPN
$2.57B
$1.79M 1.17%
200,000
+100,000
+100% +$921K
ITMN
25
CALL
DELISTED
INTERMUNE INC
ITMN
$1.67M 1.1%
+50,000
New +$1.11M
1
2 3

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q1 2014 Portfolio in Review

As of Q1 2014, Healthcare Value Capital held 56 positions worth $153M, up 12% from $136M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Healthcare Value Capital withdrew a net $12.7M in Q1 2014, closing 11 positions and reducing 10 holdings. Its most notable exit was FOREST LABORATORIES INC, an estimated $4.22M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 65% of assets, up from 61% a quarter earlier, followed by Healthcare.

Against the trend, Healthcare Value Capital opened a new position in Albany Molecular Research Inc worth $8.33M.

  • Healthcare Value Capital's largest Q1 2014 buy was Albany Molecular Research Inc: 448,200 shares worth $8.33M.
  • Healthcare Value Capital added most to Teva Pharmaceuticals in Q1 2014, an estimated $3.47M increase.
  • Healthcare Value Capital's biggest Q1 2014 reduction was ANI Pharmaceuticals, cutting an estimated $9.34M.
  • Healthcare Value Capital fully exited FOREST LABORATORIES INC in Q1 2014, selling an estimated $4.22M.
  • Healthcare Value Capital's ten largest holdings make up 60% of its $153M portfolio in Q1 2014.
  • Healthcare Value Capital opened 20 new positions and closed 11 in Q1 2014.
  • Healthcare Value Capital's portfolio value rose 12% quarter-over-quarter to $153M.

Based on Healthcare Value Capital's 13F filing for Q1 2014, filed 13 May 2014.